A Dark Vector Cognition product

Item 8. Financial Statements and Supplementary Data.

154K characters. Original on sec.gov · Markdown

Item 8. Financial Statements and Supplementary Data.

IDEX CORPORATION

CONSOLIDATED BALANCE SHEETS

As of December 31,
20132012
(In thousands except share and per share amounts)
ASSETS
Current assets
Cash and cash equivalents$439,629$318,864
Receivables — net253,226256,095
Inventories230,967234,950
Other current assets67,13171,956
Total current assets990,953881,865
Property, plant and equipment — net213,488219,161
Goodwill1,349,4561,321,727
Intangible assets — net311,227341,372
Other noncurrent assets22,45321,265
Total assets$2,887,577$2,785,390
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities
Trade accounts payable$133,312$117,341
Accrued expenses150,751150,176
Short-term borrowings1,8717,335
Dividends payable18,67516,575
Total current liabilities304,609291,427
Long-term borrowings772,005779,241
Deferred income taxes144,908121,349
Other noncurrent liabilities93,066128,375
Total liabilities1,314,5881,320,392
Commitments and contingencies (Note 8)
Shareholders’ equity
Preferred stock:
Authorized: 5,000,000 shares, $.01 per share par value; Issued: none——
Common stock:
Authorized: 150,000,000 shares, $.01 per share par value; Issued: 89,154,190 shares at December 31, 2013 and 87,732,405 shares at December 31, 2012892877
Additional paid-in capital607,766550,682
Retained earnings1,293,7401,113,541
Treasury stock at cost: 7,958,510 shares at December 31, 2013 and 5,005,518 shares at December 31, 2012(326,104)(156,699)
Accumulated other comprehensive loss(3,305)(43,403)
Total shareholders’ equity1,572,9891,464,998
Total liabilities and shareholders’ equity$2,887,577$2,785,390

See Notes to Consolidated Financial Statements.

IDEX CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

For the Years Ended December 31,
201320122011
(In thousands except per share amounts)
Net sales$2,024,130$1,954,258$1,838,451
Cost of sales1,150,7661,150,5581,099,778
Gross profit873,364803,700738,673
Selling, general and administrative expenses477,851444,490421,703
Asset impairments—198,519—
Restructuring expenses—32,47312,314
Operating income395,513128,218304,656
Other income (expense) — net(178)236(1,443)
Interest expense42,20642,25029,332
Income before income taxes353,12986,204273,881
Provision for income taxes97,91448,57480,024
Net income$255,215$37,630$193,857
Earnings per common share:
Basic earnings per common share$3.11$0.45$2.34
Diluted earnings per common share$3.09$0.45$2.32
Share data:
Basic weighted average common shares outstanding81,51782,68982,145
Diluted weighted average common shares outstanding82,48983,64183,543

See Notes to Consolidated Financial Statements.

IDEX CORPORATION

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the Years Ended December 31,
201320122011
(In thousands)
Net income$255,215$37,630$193,857
Other comprehensive income (loss)
Gains (losses) and reclassification adjustments for derivatives, net of tax4,7384,780(20,254)
Pension and other postretirement adjustments, net of tax21,788(7,159)(8,398)
Cumulative translation adjustment13,57214,445(14,108)
Comprehensive income$295,313$49,696$151,097

See Notes to Consolidated Financial Statements.

IDEX CORPORATION

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

Common Stock and Additional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive Income (Loss)Treasury StockTotal Shareholders’ Equity
Cumulative Translation AdjustmentRetirement Benefits AdjustmentsCumulative Unrealized Gain (Loss) on Derivatives
(In thousands except share and per share amounts)
Balance, December 31, 2010$442,117$1,005,040$38,302$(30,088)$(20,923)$(58,788)$1,375,660
Net income—193,857————193,857
Cumulative translation adjustment——(14,108)———(14,108)
Net change in retirement obligations (net of tax benefit of $4,222)———(8,398)——(8,398)
Net change on derivatives designated as cash flow hedges (net of tax benefit of $12,500)————(20,254)—(20,254)
Issuance of 1,596,145 shares of common stock from issuance of unvested shares, exercise of stock options and deferred compensation plans (net of tax of $4,150)37,621—————37,621
Share-based compensation11,250—————11,250
Unvested shares surrendered for tax withholding—————(6,008)(6,008)
Cash dividends declared — $.68 per common share outstanding—(56,485)————(56,485)
Balance, December 31, 2011$490,988$1,142,412$24,194$(38,486)$(41,177)$(64,796)$1,513,135
Net income—37,630————37,630
Cumulative translation adjustment——14,445———14,445
Net change in retirement obligations (net of tax benefit of $1,647)———(7,159)——(7,159)
Net change on derivatives designated as cash flow hedges (net of tax of $2,791)————4,780—4,780
Issuance of 1,826,977 shares of common stock from issuance of unvested shares, exercise of stock options and deferred compensation plans (net of tax of $4,865)49,721—————49,721
Repurchase of 2,182,946 shares of common stock—————(89,563)(89,563)
Share-based compensation10,850—————10,850
Unvested shares surrendered for tax withholding—————(2,340)(2,340)
Cash dividends declared — $.80 per common share outstanding—(66,501)————(66,501)
Balance, December 31, 2012$551,559$1,113,541$38,639$(45,645)$(36,397)$(156,699)$1,464,998
Net income—255,215————255,215
Cumulative translation adjustment——13,572———13,572
Net change in retirement obligations (net of tax of $13,085)———21,788——21,788
Net change on derivatives designated as cash flow hedges (net of tax of $2,692)————4,738—4,738
Issuance of 1,471,568 shares of common stock from issuance of unvested shares, exercise of stock options and deferred compensation plans (net of tax of $4,514)43,749—————43,749
Repurchase of 2,916,280 shares of common stock—————(167,503)(167,503)
Share-based compensation13,350—————13,350
Unvested shares surrendered for tax withholding—————(1,902)(1,902)
Cash dividends declared — $.89 per common share outstanding—(75,016)————(75,016)
Balance, December 31, 2013$608,658$1,293,740$52,211$(23,857)$(31,659)$(326,104)$1,572,989

See Notes to Consolidated Financial Statements.

IDEX CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Years Ended December 31,
201320122011
(In thousands)
Cash flows from operating activities
Net income$255,215$37,630$193,857
Adjustments to reconcile net income to net cash provided by operating activities:
Gain on sale of fixed assets(96)—(2,831)
Asset impairments2,747198,519—
Depreciation and amortization35,00736,82736,882
Amortization of intangible assets44,32741,48535,504
Amortization of debt issuance expenses1,7031,6851,263
Share-based compensation expense16,99313,10212,076
Deferred income taxes(3,156)(37,229)(3,576)
Excess tax benefit from share-based compensation(8,560)(4,474)(5,298)
Non-cash interest expense associated with forward starting swaps7,4307,6373,570
Forward starting interest rate contract settlement——(38,707)
Changes in (net of the effect from acquisitions):
Receivables6,19512,747(16,488)
Inventories9,08823,799(607)
Other current assets6,562(12,127)877
Trade accounts payable15,460(1,376)(8,645)
Accrued expenses11,7909,9447,411
Other — net817(1,989)1,953
Net cash flows provided by operating activities401,522326,180217,241
Cash flows from investing activities
Purchases of property, plant and equipment(31,536)(35,807)(35,175)
Acquisition of businesses, net of cash acquired(36,849)(68,930)(443,634)
Proceeds from fixed asset disposals567—12,651
Other — net(344)(529)(3,379)
Net cash flows used in investing activities(68,162)(105,266)(469,537)
Cash flows from financing activities
Borrowings under revolving facilities and credit facilities for acquisitions34,64835,000365,000
Borrowings under revolving facilities38,45394,479471,222
Proceeds from issuance of 4.2% Senior Notes——349,125
Payments under revolving facilities, credit facilities and term loan(89,478)(158,825)(906,115)
Debt issuance costs——(5,451)
Dividends paid(72,905)(64,087)(54,613)
Proceeds from stock option exercises35,30645,77133,064
Excess tax benefit from share-based compensation8,5604,4745,298
Purchase of common stock(167,503)(89,563)—
Unvested shares surrendered for tax withholding(1,902)(2,340)(6,008)
Other(4,224)(1,394)1,890
Net cash flows (used in) provided by financing activities(219,045)(136,485)253,412
Effect of exchange rate changes on cash and cash equivalents6,4504,176(5,993)
Net increase (decrease) in cash120,76588,605(4,877)
Cash and cash equivalents at beginning of year318,864230,259235,136
Cash and cash equivalents at end of period$439,629$318,864$230,259
Supplemental cash flow information
Cash paid for:
Interest$33,432$32,639$27,749
Income taxes73,65787,60366,087
Significant non-cash activities:
Contingent consideration for acquisition—8,3703,000
Debt acquired with acquisition of business—4,6801,400

See Notes to Consolidated Financial Statements.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMETNS

  1. Significant Accounting Policies

Business

IDEX is an applied solutions company specializing in fluid and metering technologies, health and science technologies, and fire, safety and other diversified products built to its customers’ specifications. IDEX's products are sold in niche markets to a wide range of industries throughout the world. The Company’s products include industrial pumps, compressors, flow meters, injectors and valves, and related controls for use in a wide variety of process applications; precision fluidics solutions, including pumps, valves, degassing equipment, corrective tubing, fittings, and complex manifolds, precision photonic solutions, optical filters and specialty medical equipment and devices used in life science applications; precision-engineered equipment for dispensing, metering and mixing paints; refinishing equipment; and engineered products for industrial and commercial markets, including fire and rescue, transportation equipment, oil and gas, electronics, and communications. These activities are grouped into three reportable segments: Fluid & Metering Technologies, Health & Science Technologies and Fire & Safety/Diversified Products.

Principles of Consolidation

The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and accounts have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The principal areas of estimation reflected in the financial statements are revenue recognition, sales returns and allowances, allowance for doubtful accounts, inventory valuation, recoverability of long-lived assets, income taxes, product warranties, contingencies and litigation, insurance-related items, defined benefit retirement plans and purchase accounting related to acquisitions.

Revenue Recognition

The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the sales price is fixed or determinable, and collectability of the sales price is reasonably assured. For product sales, delivery does not occur until the products have been shipped and risk of loss has been transferred to the customer. Revenue from services is recognized when the services are provided or ratably over the contract term. Some arrangements with customers may include multiple deliverables, including the combination of products and services. In such cases the Company has identified these as separate elements in accordance with ASC 605-25 and recognizes revenue consistent with the policy for each separate element based on the relative selling price method. Revenues from certain long-term contracts are recognized on the percentage-of-completion method. Percentage-of-completion is measured principally by the percentage of costs incurred to date for each contract to the estimated total costs for such contract at completion. Provisions for estimated losses on uncompleted long-term contracts are made in the period in which such losses are determined. Due to uncertainties inherent in the estimation process, it is reasonably possible that completion costs, including those arising from contract penalty provisions and final contract settlements, will be revised in the near-term. Such revisions to costs and income are recognized in the period in which the revisions are determined.

The Company records allowances for discounts, product returns and customer incentives at the time of sale as a reduction of revenue as such allowances can be reliably estimated based on historical experience and known trends. The Company also offers product warranties and accrues its estimated exposure for warranty claims at the time of sale based upon the length of the warranty period, warranty costs incurred and any other related information known to the Company.

Shipping and Handling Costs

Shipping and handling costs are included in cost of sales and are recognized as a period expense during the period in which they are incurred.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Advertising Costs

Advertising costs of $14.6 million, $15.3 million and $13.4 million for 2013, 2012 and 2011, respectively, are expensed as incurred within Selling, general and administrative expenses.

Cash and Cash Equivalents

The Company considers all highly liquid instruments purchased with an original maturity of 90 days or less to be cash and cash equivalents.

Allowance for Doubtful Accounts

The Company maintains allowances for doubtful accounts for estimated losses as a result of customer’s inability to make required payments. Management evaluates the aging of the accounts receivable balances, the financial condition of its customers, historical trends and the time outstanding of specific balances to estimate the amount of accounts receivables that may not be collected in the future and records the appropriate provision.

Inventories

The Company states inventories at the lower of cost or market. Cost, which includes material, labor, and factory overhead, is determined on a FIFO basis. We make adjustments to reduce the cost of inventory to its net realizable value, if required, at the business unit level for estimated excess, obsolescence or impaired balances. Factors influencing these adjustments include changes in market demand, product life cycle and engineering changes.

Impairment of Long-Lived Assets

Long-lived assets are reviewed for impairment upon the occurrence of events or changes in circumstances that indicate that the carrying value of the assets may not be recoverable, as measured by comparing their net book value to the projected undiscounted future cash flows generated by their use. Impaired assets are recorded at their estimated fair value based on a discounted cash flow analysis.

Goodwill and Indefinite-Lived Intangible Assets

In accordance with ASC 350, the Company reviews the carrying value of goodwill and indefinite-lived intangible assets annually on October 31, or upon the occurrence of events or changes in circumstances that indicate that the carrying value of the goodwill or intangible assets may not be recoverable. The Company evaluates the recoverability of these assets based on the estimated fair value of each of the fifteen reporting units and the indefinite-lived intangible asset. See Note 4 for a further discussion on goodwill and intangible assets.

Borrowing Expenses

Expenses incurred in securing and issuing debt are capitalized and included in Other noncurrent assets. These assets are amortized over the life of the related borrowing and the related amortization is included in Interest expense in the Consolidated Statements of Operations.

Earnings per Common Share

Earnings per common share (“EPS”) is computed by dividing net income by the weighted average number of shares of common stock (basic) plus common stock equivalents (diluted) outstanding during the year. Common stock equivalents consist of stock options, which have been included in the calculation of weighted average shares outstanding using the treasury stock method, unvested shares, performance share units, and shares issuable in connection with certain deferred compensation agreements ("DCUs").

ASC 260 concludes that all outstanding unvested share-based payment awards that contain rights to nonforfeitable dividends participate in undistributed earnings with common shareholders. If awards are considered participating securities, the Company is required to apply the two-class method of computing basic and diluted earnings per share. The Company has determined that its outstanding unvested shares are participating securities. Accordingly, earnings per common share were computed using the two-class method prescribed by ASC 260. Net income attributable to common shareholders was reduced by $1.2 million, $0.1 million and $1.2 million in 2013, 2012 and 2011, respectively.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Basic weighted average shares outstanding reconciles to diluted weighted average shares outstanding as follows:

201320122011
(In thousands)
Basic weighted average common shares outstanding81,51782,68982,145
Dilutive effect of stock options, unvested shares, performance share units and DCUs9729521,398
Diluted weighted average common shares outstanding82,48983,64183,543

Options to purchase approximately zero, 1.2 million and 0.7 million shares of common stock in 2013, 2012 and 2011, respectively, were not included in the computation of diluted EPS because the effect of their inclusion would have been antidilutive.

Share-Based Compensation

The Company accounts for share-based payments in accordance with ASC 718. Accordingly, the Company expenses the fair value of awards made under its share-based compensation plans. That cost is recognized in the consolidated financial statements over the requisite service period of the grants. See Note 13 for further discussion on share-based compensation.

Depreciation and Amortization

Property and equipment are stated at cost, with depreciation and amortization provided using the straight-line method over the following estimated useful lives:

Land improvements8 to 12 years
Buildings and improvements8 to 30 years
Machinery, equipment and other3 to 12 years
Office and transportation equipment3 to 10 years

Certain identifiable intangible assets are amortized over their estimated useful lives using the straight-line method. The estimated useful lives used in the computation of amortization of identifiable intangible assets are as follows:

Patents5 to 17 years
Trade names10 to 20 years
Customer relationships4.5 to 20 years
Non-compete agreements2.5 to 3 years
Unpatented technology and other4.5 to 20 years

Research and Development Expenditures

Costs associated with research and development are expensed in the period incurred and are included in Cost of sales within the Consolidated Statements of Operations. Research and development expenses, which include costs associated with developing new products and major improvements to existing products, were $33.0 million, $36.4 million and $36.0 million in 2013, 2012 and 2011, respectively.

Foreign Currency Translation

The functional currency of substantially all operations outside the United States is the respective local currency. Accordingly, those foreign currency balance sheet accounts have been translated using the exchange rates in effect as of the balance sheet date. Income statement amounts have been translated using the average exchange rate for the year. The gains and losses resulting from changes in exchange rates from year to year have been reported in Accumulated other comprehensive loss in the Consolidated Balance Sheets. The effect of transaction gains and losses is reported within Other income (expense)-net in the Consolidated Statements of Operations.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Income Taxes

Income tax expense includes United States, state, local and international income taxes. Deferred tax assets and liabilities are recognized for the tax consequences of temporary differences between the financial reporting and the tax basis of existing assets and liabilities and for loss carryforwards. The tax rate used to determine the deferred tax assets and liabilities is the enacted tax rate for the year and manner in which the differences are expected to reverse. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.

Concentration of Credit Risk

The Company is not dependent on a single customer, the largest of which accounted for less than 2% of net sales for all years presented.

Recently Issued Accounting Pronouncements

In February 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2013-02 which requires additional disclosures regarding the reporting of reclassifications out of accumulated other comprehensive income. ASU 2013-02 requires an entity to present, either on the face of the statement where net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting period. This guidance is effective for reporting periods beginning after December 15, 2012. The Company adopted this guidance effective January 1, 2013 and its adoption did not impact the consolidated financial position, results of operations or cash flows of the Company. See Note 14 for a further discussion on other comprehensive income (loss).

  1. Restructuring

During 2012 and 2011 the Company recorded restructuring costs as a part of the 2011 restructuring initiatives that support the implementation of key strategic efforts designed to facilitate long-term sustainable growth through cost reduction actions, primarily consisting of employee reductions and facility rationalization. The costs incurred related to these initiatives are included in Restructuring expenses in the Consolidated Statements of Operations while the related accruals are included in Accrued expenses in the Consolidated Balance Sheets. Severance costs primarily consist of severance benefits through payroll continuation, COBRA subsidies, outplacement services, conditional separation costs and employer tax liabilities, while exit costs primarily consist of asset disposals or impairments, the termination of a defined benefit plan, legal costs and relocation charges.

2011 Initiatives

During 2012 and 2011 the Company recorded pre-tax restructuring expenses totaling $32.5 million and $12.3 million, respectively, related to our 2011 restructuring initiative for exit costs and employee severance related to employee reductions across various functional areas as well as facility rationalization. The 2011 restructuring initiatives included severance benefits for 491 employees in 2012 and 292 employees in 2011. The 2011 initiative was completed by the end of 2012 and no further restructuring is currently planned. Severance payments were fully paid in 2013 using cash from operations.

Pre-tax restructuring expenses by segment, for 2012, were as follows:

Severance CostsExit CostsTotal
(In thousands)
Fluid & Metering Technologies$6,226$36$6,262
Health & Science Technologies11,2233,52114,744
Fire & Safety/Diversified Products3,2265,1148,340
Corporate/Other2,8442833,127
Total restructuring costs$23,519$8,954$32,473

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Pre-tax restructuring expenses by segment, for 2011, were as follows:

Severance CostsExit CostsTotal
(In thousands)
Fluid & Metering Technologies$2,800$61$2,861
Health & Science Technologies2,0071232,130
Fire & Safety/Diversified Products4,4307975,227
Corporate/Other2,096—2,096
Total restructuring costs$11,333$981$12,314

Restructuring accruals of $10.9 million at December 31, 2012 are reflected in Accrued expenses in our Consolidated Balance Sheets as follows:

2011 Initiative
(In thousands)
Balance at January 1, 2012$5,875
Restructuring expenses32,473
Payments, utilization and other(27,461)
Balance at December 31, 201210,887
Restructuring expenses—
Payments, utilization and other(10,887)
Balance at December 31, 2013$—

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

  1. Balance Sheet Components
December 31,
20132012
(In thousands)
RECEIVABLES
Customers$255,992$257,114
Other3,0754,577
Total259,067261,691
Less allowance for doubtful accounts5,8415,596
Total receivables — net$253,226$256,095
INVENTORIES
Raw materials and components parts$133,470$139,229
Work in process41,89533,025
Finished goods55,60262,696
Total$230,967$234,950
PROPERTY, PLANT AND EQUIPMENT
Land and improvements$32,723$31,787
Buildings and improvements150,316141,952
Machinery, equipment and other300,858288,542
Office and transportation equipment95,92395,920
Construction in progress9,20112,040
Total589,021570,241
Less accumulated depreciation and amortization375,533351,080
Total property, plant and equipment — net$213,488$219,161
ACCRUED EXPENSES
Payroll and related items$63,297$55,618
Management incentive compensation20,94915,974
Income taxes payable11,74610,284
Insurance7,7418,974
Warranty4,8884,875
Deferred revenue9,4559,682
Restructuring—10,887
Liability for uncertain tax positions1,2012,679
Accrued interest1,3541,713
Contingent consideration for acquisition—3,528
Other30,12025,962
Total accrued expenses$150,751$150,176
OTHER NONCURRENT LIABILITIES
Pension and retiree medical obligations$67,777$96,853
Liability for uncertain tax positions4,6244,989
Deferred revenue5,5786,534
Contingent consideration for acquisition—5,515
Other15,08714,484
Total other noncurrent liabilities$93,066$128,375

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

201320122011
(In thousands)
VALUATION AND QUALIFYING ACCOUNTS(1)
Beginning balance January 1$5,596$5,860$5,322
Charged to costs and expenses, net of recoveries2,2886531,044
Utilization(1,921)(1,151)(917)
Currency translation and other(122)234411
Ending balance December 31$5,841$5,596$5,860
(1)Includes provision for doubtful accounts, sales returns and sales discounts granted to customers.
  1. Goodwill and Intangible Assets

The changes in the carrying amount of goodwill for 2013 and 2012, by business segment, were as follows:

Fluid & Metering TechnologiesHealth & Science TechnologiesFire & Safety/ Diversified ProductsTotal
(In thousands)
Goodwill$541,640$648,906$270,910$1,461,456
Accumulated impairment losses——(30,090)(30,090)
Balance at January 1, 2012541,640648,906240,8201,431,366
Acquisition adjustments—1,424—1,424
Acquisitions (Note 12)—50,387—50,387
Foreign currency translation3,4062,3073,3789,091
Goodwill impairment(20,721)(149,820)—(170,541)
Balance at December 31, 2012524,325553,204244,1981,321,727
Acquisitions (Note 12)—17,994—17,994
Foreign currency translation3,7194775,5399,735
Balance at December 31, 2013$528,044$571,675$249,737$1,349,456

ASC 350 requires that goodwill be tested for impairment at the reporting unit level on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. Goodwill represents the purchase price in excess of the net amount assigned to assets acquired and liabilities assumed.

Goodwill and other acquired intangible assets with indefinite lives were tested for impairment as of October 31, 2013, the Company's annual impairment date. In assessing the fair value of the reporting units, the Company considers both the market approach and income approach. Under the market approach, the fair value of the reporting unit is based on comparing the reporting unit to comparable publicly traded companies. Under the income approach, the fair value of the reporting unit is based on the present value of estimated future cash flows. The income approach is dependent on a number of significant management assumptions including estimates of operating results, capital expenditures, other operating costs and discount rates. Weighting was equally attributed to both the market and income approaches (50% each) in arriving at the fair value of the reporting units.

In 2013, there were no triggering events or changes in circumstances that would have required a review other than as of our annual test date. Based on the results of our measurement at October 31, 2013, all reporting units had a fair value that was significantly in excess of carrying value, except for our IOP reporting unit, which had a fair value greater than 10% above carrying value. The IOP reporting unit was written down to its fair value in 2012 as result of our goodwill impairment and thus the fair value continues to be near the carrying value. In 2012, as a result of our annual impairment test for the IOP reporting unit and as a result of the reorganization of certain FMT reporting units, the Company determined that the fair value of the IOP and WST reporting units was less than the carrying value of the net assets of the reporting units, and thus the Company performed step two of the goodwill impairment test. In step two of the goodwill impairment test, the Company determined the

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

implied fair value of the goodwill and compared it to the carrying value, which resulted in a $149.8 million goodwill impairment charge at the IOP reporting unit and a $20.7 million goodwill impairment charge at the WST reporting unit.

The following table provides the gross carrying value and accumulated amortization for each major class of intangible asset at December 31, 2013 and 2012:

At December 31, 2013At December 31, 2012
Gross Carrying AmountAccumulated AmortizationNetWeighted Average LifeGross Carrying AmountAccumulated AmortizationNet
(In thousands)(In thousands)
Amortizable intangible assets:
Patents$10,673$(5,179)$5,49411$10,650$(4,273)$6,377
Trade names104,582(28,310)76,27216103,113(21,603)81,510
Customer relationships242,674(121,092)121,58210230,196(93,273)136,923
Non-compete agreements3,769(3,272)49733,505(2,827)678
Unpatented technology75,528(32,905)42,6231174,758(24,211)50,547
Other6,958(4,299)2,659106,841(3,604)3,237
Total amortizable intangible assets444,184(195,057)249,127429,063(149,791)279,272
Unamortized intangible assets:
Banjo trade name62,100—62,10062,100—62,100
Total intangible assets$506,284$(195,057)$311,227$491,163$(149,791)$341,372

The unamortized Banjo trade name was determined to be an indefinite lived intangible asset which is tested for impairment on an annual basis in accordance with ASC 350 or more frequently if events or changes in circumstances indicate that the asset might be impaired. The Company uses the relief-from-royalty method, a form of the income approach. The relief-from-royalty method is dependent of a number of significant management assumptions, including estimates of revenues, royalty rates and discount rates.

In 2013, there were no triggering events or changes in circumstances that would have required a review other than as of our annual test date and the Company concluded that the fair value of the Banjo trade name was in excess of the carrying value as of October 31, 2013.

In 2012, as a result of our annual impairment test, the Company concluded that the fair value of the CVI Melles Griot trade names within the IOP reporting unit was less than the carrying value, resulting in a $21.0 million impairment charge. The Company also determined that the CVI Melles Griot trade names no longer had an indefinite life and reclassified the remaining $26.0 million to definite lived assets that will be amortized over a remaining useful life of 15 years.

A long-lived asset impairment exists when the carrying amount of the asset exceeds its fair value. Assessments of possible impairments of long-lived assets are made when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable through future operations. The amount and timing of impairment charges for these assets require the estimation of future cash flows and the fair value of the related assets. In 2013, the Company concluded that certain long lived assets had a fair value that was less than the carrying value of the assets, resulting in $2.7 million of impairment charges. In 2012, the Company concluded that certain long lived assets within the WST reporting unit had a fair value that was less than the carrying value of the assets, resulting in a $7.0 million impairment charge.

Amortization of intangible assets was $44.3 million, $41.5 million and $35.5 million in 2013, 2012 and 2011, respectively. Based on intangible asset balances as of December 31, 2013, amortization expense is expected to approximate $43.3 million in 2014, $41.1 million in 2015, $39.1 million in 2016, $30.0 million in 2017 and $18.3 million in 2018.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

  1. Borrowings

Borrowings at December 31, 2013 and 2012 consisted of the following:

20132012
(In thousands)
Revolving Facility$10,000$21,000
4.2% Senior Notes, due December 2021349,272349,197
4.5% Senior Notes, due December 2020298,828298,689
2.58% Senior Euro Notes, due June 2015111,505107,042
Other borrowings4,27110,648
Total borrowings773,876786,576
Less current portion1,8717,335
Total long-term borrowings$772,005$779,241

On June 27, 2011, the Company and certain of its subsidiaries entered into a credit agreement (the “Credit Agreement”), as borrowers with Bank of America, N.A., as administrative agent, swing line lender and an issuer of letters of credit, and other lenders party thereto which provided for a new revolving credit facility (the “Revolving Facility”). The Revolving Facility replaced the Company’s previous $600.0 million credit facility, which expired in December 2011.

The Revolving Facility is in an aggregate principal amount of $700.0 million with a maturity date of June 27, 2016. Up to $75.0 million of the Revolving Facility is available for the issuance of letters of credit. Additionally, up to $25.0 million of the Revolving Facility is available to the Company for swing line loans, available on a same-day basis.

Proceeds of the Revolving Facility are available for working capital and other general corporate purposes, including refinancing existing debt of the Company and its subsidiaries. The Company may request increases in the lending commitments under the Credit Agreement, but the aggregate lending commitments may not exceed $950.0 million. The Company has the right, subject to certain conditions set forth in the Credit Agreement, to designate certain foreign subsidiaries of the Company as borrowers under the Credit Agreement. In connection with any such designation, the Company is required to guarantee the obligations of any such subsidiaries under the Credit Agreement. Under the Credit Agreement, Fast & Fluid Management Europe B.V., (“FME”) and IDEX UK Ltd. (“IDEX UK”) were approved by the lenders as designated borrowers. At December 31, 2012, FME and IDEX UK had no borrowings under the Revolving Facility.

Borrowings under the Revolving Facility bear interest, at either an alternate base rate or an adjusted LIBOR rate plus, in each case, an applicable margin. Such applicable margin is based on the Company’s senior, unsecured, long-term debt rating and can range from .875% to 1.70%. Based on the Company’s credit rating at December 31, 2013, the applicable margin was 1.05%. Interest is payable (a) in the case of base rate loans, quarterly, and (b) in the case of LIBOR rate loans, on the maturity date of the borrowing, or quarterly from the effective date for borrowings exceeding three months. An annual Revolving Facility fee, also based on the Company’s credit rating, is currently 20 basis points and is payable quarterly.

The Credit Agreement contains affirmative and negative covenants that the Company believes are usual and customary for senior unsecured credit agreements, including a financial covenant requiring a maximum leverage ratio of a 3.25 to 1.0, which is the ratio of the Company’s consolidated total debt to its consolidated EBITDA, each as defined in the Credit Agreement.

The Credit Agreement also contains customary events of default (subject to grace periods, as appropriate) including among others: nonpayment of principal, interest or fees; breach of the representations or warranties in any material respect; breach of the financial, affirmative or negative covenants; payment default on, or acceleration of, other material indebtedness; bankruptcy or insolvency; material judgments entered against the Company or any of its subsidiaries; certain specified events under the Employee Retirement Income Security Act of 1974, as amended; certain changes in control of the Company; and the invalidity or unenforceability of the Credit Agreement or other documents associated with the Credit Agreement.

At December 31, 2013, $10.0 million was outstanding under the Revolving Facility, with $8.7 million of outstanding letters of credit, resulting in net available borrowing capacity under the Revolving Facility at December 31, 2013 of approximately $681.3 million.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

On June 9, 2010, the Company completed a private placement of €81.0 million ($96.8 million) aggregate principal amount of 2.58% Series 2010 Senior Euro Notes due June 9, 2015 (“2.58% Senior Euro Notes”) pursuant to a Master Note Purchase Agreement, dated June 9, 2010 (the “Purchase Agreement”). The Purchase Agreement provides for the issuance of additional series of notes in the future, provided that the aggregate principal amount outstanding under the agreement at any time does not exceed $750.0 million. The 2.58% Senior Euro Notes bear interest at a rate of 2.58% per annum, which is payable semi-annually in arrears on each June 9th and December 9th and will mature on June 9, 2015. The 2.58% Senior Euro Notes are unsecured obligations of the Company and rank pari passu in right of payment with all of the Company’s other senior debt. The Company may at any time prepay all or any portion of the 2.58% Senior Euro Notes; provided that any such portion is greater than 5% of the aggregate principal amount of Notes then outstanding under the Purchase Agreement. In the event of a prepayment, the Company would be required to pay an amount equal to par plus accrued interest plus a make-whole premium. The Purchase Agreement contains certain covenants that restrict the Company’s ability to, among other things, transfer or sell assets, create liens and engage in certain mergers or consolidations. In addition, the Company must comply with a leverage ratio and interest coverage ratio as set forth in the Purchase Agreement. The Purchase Agreement provides for customary events of default. In the case of an event of default arising from specified events of bankruptcy or insolvency, all outstanding 2.58% Senior Euro Notes will become due and payable immediately without further action or notice. In the case of payment events of defaults, any holder of the 2.58% Senior Euro Notes affected thereby may declare all the 2.58% Senior Euro Notes held by it due and payable immediately. In the case of any other event of default, a majority of the holders of the 2.58% Senior Euro Notes may declare all the 2.58% Senior Euro Notes to be due and payable immediately.

On December 6, 2010, the Company completed a public offering of $300.0 million 4.5% senior notes due December 15, 2020 (“4.5% Senior Notes”). The net proceeds from the offering of $295.7 million, after deducting a $1.6 million issuance discount, a $1.9 million underwriting commission and $0.8 million offering expenses, were used to repay $250.0 million of outstanding bank indebtedness, with the balance used for general corporate purposes. The 4.5% Senior Notes bear interest at a rate of 4.5% per annum, which is payable semi-annually in arrears on each June 15th and December 15th. The Company may redeem all or a portion of the 4.5% Senior Notes at any time prior to maturity at the redemption prices set forth in the Note Indenture governing the 4.5% Senior Notes. The Company may issue additional debt from time to time pursuant to the Indenture. The Indenture and 4.5% Senior Notes contain covenants that limit the Company’s ability to, among other things, incur certain liens securing indebtedness, engage in certain sale-leaseback transactions, and enter into certain consolidations, mergers, conveyances, transfers or leases of all or substantially all the Company’s assets. The terms of the 4.5% Senior Notes also require the Company to make an offer to repurchase the 4.5% Senior Notes upon a change of control triggering event (as defined in the Indenture) at a price equal to 101% of their principal amount plus accrued and unpaid interest, if any.

On December 9, 2011, the Company completed a public offering of $350.0 million 4.2% senior notes due December 15, 2021 (“4.2% Senior Notes”). The net proceeds from the offering of $346.2 million, after deducting a $0.9 million issuance discount, a $2.3 million underwriting commission and $0.6 million offering expenses, were used to repay $306.0 million of outstanding bank indebtedness, with the balance used for general corporate purposes. The 4.2% Senior Notes bear interest at a rate of 4.2% per annum, which is payable semi-annually in arrears on each June 15th and December 15th. The Company may redeem all or a portion of the 4.2% Senior Notes at any time prior to maturity at the redemption prices set forth in the Note Indenture governing the 4.2% Senior Notes. The Company may issue additional debt from time to time pursuant to the Indenture. The Indenture and 4.2% Senior Notes contain covenants that limit the Company’s ability to, among other things, incur certain liens securing indebtedness, engage in certain sale-leaseback transactions, and enter into certain consolidations, mergers, conveyances, transfers or leases of all or substantially all the Company’s assets. The terms of the 4.2% Senior Notes also require the Company to make an offer to repurchase the 4.2% Senior Notes upon a change of control triggering event (as defined in the Indenture) at a price equal to 101% of their principal amount plus accrued and unpaid interest, if any.

Other borrowings of $4.3 million at December 31, 2013 were comprised of capital leases, debt at international locations maintained for working capital purposes and international debt as a result of acquisitions. Interest is payable on the outstanding debt balances at the international locations at rates ranging from 0.3% to 1.5% per annum.

There are two key financial covenants that the Company is required to maintain in connection with the Revolving Facility and 2.58% Senior Euro Notes. The most restrictive financial covenants under these debt instruments require a minimum interest coverage ratio of 3.0 to 1 and a maximum leverage ratio of 3.25 to 1. At December 31, 2013, the Company was in compliance with both of these financial covenants. There are no financial covenants relating to the 4.5% Senior Notes or 4.2% Senior Notes; however, both are subject to cross-default provisions.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Total borrowings at December 31, 2013 have scheduled maturities as follows (in thousands):

2014$1,871
2015112,085
201610,530
20171,190
2018100
Thereafter648,100
Total borrowings$773,876
  1. Derivative Instruments

The Company enters into cash flow hedges to reduce the exposure to variability in certain expected future cash flows. The type of cash flow hedges the Company enters into includes foreign currency contracts and interest rate exchange agreements that effectively convert a portion of floating-rate debt to fixed-rate debt and are designed to reduce the impact of interest rate changes on future interest expense.

The effective portion of gains or losses on interest rate exchange agreements is reported in accumulated other comprehensive income (loss) in shareholders’ equity and reclassified into net income in the same period or periods in which the hedged transaction affects net income. The remaining gain or loss in excess of the cumulative change in the present value of future cash flows or the hedged item, if any, is recognized into net income during the period of change.

Fair values relating to derivative financial instruments reflect the estimated amounts that the Company would receive or pay to sell or buy the contracts based on quoted market prices of comparable contracts at each balance sheet date.

On April 15, 2010, the Company entered into a forward starting interest rate contract with a notional amount of $300.0 million with a settlement date in December 2010. This contract was entered into in anticipation of the issuance of the 4.5% Senior Notes and was designed to lock in the market interest rate as of April 15, 2010. In December 2010, the Company settled and paid this interest rate contract for $31.0 million. The $31.0 million is being amortized into interest expense over the 10 year term of the 4.5% Senior Notes, which results in an effective interest rate of 5.8%.

On July 12, 2011, the Company entered into a forward starting interest rate contract with a notional amount of $350.0 million and a settlement date of September 30, 2011. This contract was entered into in anticipation of the issuance of the 4.2% Senior Notes and was designed to lock in the market interest rate as of July 12, 2011. On September 29, 2011, the Company settled this interest rate contract for $34.7 million with a payment made on October 3, 2011. Simultaneously, the Company entered into a separate interest rate contract with a notional amount of $350.0 million and a settlement date of February 28, 2012. The contract was entered into in anticipation of the expected issuance of the 4.2% Senior Notes and was designed to maintain the market rate as of July 12, 2011. In December 2011, the Company settled and paid the September interest rate contract for $4.0 million, resulting in a total settlement of $38.7 million. Of the $38.7 million, $0.8 million was recognized as other expense in 2011 and the balance of $37.9 million is being amortized into interest expense over the 10 year term of the 4.2% Senior Notes, which results in an effective interest rate of 5.3%.

As of December 31, 2013 and 2012, the Company did not have any interest rate or foreign exchange contracts outstanding.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The following table summarizes the gain (loss) recognized and the amounts and location of income (expense) and gain (loss) reclassified into income for interest rate contracts and foreign currency contracts for the year ended December 31, 2013 and 2012:

Loss Recognized in Other Comprehensive IncomeIncome (Expense) and Gain (Loss) Reclassified into IncomeIncome Statement Caption
Twelve Months Ended December 31,
201320122011201320122011
(In thousands)
Interest rate agreements$—$—$—$(7,430)$(7,637)$(3,570)Interest expense

Approximately $7.2 million of the pre-tax amount included in accumulated other comprehensive loss in shareholders’ equity at December 31, 2013 will be recognized to net income over the next 12 months as the underlying hedged transactions are realized.

  1. Fair Value Measurements

ASC 820 “Fair Value Measurements and Disclosures” defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The standard utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

•Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
•Level 2: Inputs, other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

The following table summarizes the basis used to measure the Company’s financial assets (liabilities) at fair value on a recurring basis in the balance sheet at December 31, 2013 and 2012:

Basis of Fair Value Measurements
Balance at December 31, 2013Level 1Level 2Level 3
(In thousands)
Money market investments$27,871$27,871$—$—
Available for sale securities3,2553,255——
Balance at December 31, 2012Level 1Level 2Level 3
(In thousands)
Money market investments$11,165$11,165$—$—
Available for sale securities2,8622,862——
Contingent consideration(9,043)——(9,043)

There were no transfers of assets or liabilities between Level 1 and Level 2 in 2013 or 2012.

In determining the initial fair value of the contingent consideration potentially due on the acquisition of Matcon, the Company used probability weighted estimates adjusted for the time value of money. At December 31, 2012, the Matcon contingent consideration liability was valued at $9.0 million, of which $8.4 million was recorded as part of the purchase price as of the opening balance sheet date and the remaining $0.6 was recognized in Selling, general and administrative expenses in

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

the fourth quarter of 2012. At December 31, 2012, $3.5 million of the contingent consideration was included in Accrued expenses and $5.5 million of contingent consideration was recorded in Other noncurrent liabilities in the Consolidated Balance Sheet. In April 2013, the Company paid $3.8 million on the contingent consideration arrangement based on Matcon's 2012 operating results. In November 2013, the Company paid $1.1 million of the contingent consideration arrangement based on a settlement agreement with the sellers and the remaining $4.1 million was recognized as a benefit within Selling, general and administrative expenses.

The carrying value of our cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair values because of the short term nature of these instruments. At December 31, 2013, the fair value of our Revolving Facility, 2.58% Senior Euro Notes, 4.5% Senior Notes and 4.2% Senior Notes, based on quoted market prices and current market rates for debt with similar credit risk and maturity, was approximately $772.9 million compared to the carrying value of $769.6 million. This fair value measurement is classified as Level 2 within the fair value hierarchy since it is determined based upon significant inputs observable in the market, including interest rates on recent financing transactions to entities with a credit rating similar to ours.

  1. Commitments and Contingencies

The Company leases certain office facilities, warehouses and data processing equipment under operating leases. Rental expense totaled $18.9 million, $18.4 million and $19.0 million in 2013, 2012 and 2011, respectively.

The aggregate future minimum lease payments for operating and capital leases as of December 31, 2013 were as follows:

OperatingCapital
(In thousands)
2014$15,426$564
201511,811604
20167,742548
20175,1771,192
20183,964100
2019 and thereafter5,945—
$50,065$3,008

Warranty costs are provided for at the time of sale. The warranty provision is based on historical costs and adjusted for specific known claims. A rollforward of the warranty reserve is as follows:

201320122011
(In thousands)
Beginning balance January 1st$4,875$4,417$3,831
Provision for warranties3,8455,3984,648
Claim settlements(3,865)(5,214)(4,443)
Other adjustments, including acquisitions and currency translation33274381
Ending balance December 31st$4,888$4,875$4,417

The Company is party to various legal proceedings arising in the ordinary course of business, none of which is expected to have a material effect on its business, financial condition, results of operations or cash flow.

  1. Common and Preferred Stock

On November 8, 2013, the Company’s Board of Directors approved an increase in the authorized level for repurchases of common stock by $300.0 million. Repurchases under the program will be funded with future cash flow generation. During 2013, the Company purchased a total of 2.9 million shares at a cost of $167.5 million compared to 2.2 million shares purchased at a cost of $89.6 million in 2012. As of December 31, 2013 there was $368 million remaining under authorized repurchases.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

At December 31, 2013 and 2012, the Company had 150 million shares of authorized common stock, with a par value of $.01 per share and 5 million shares of authorized preferred stock with a par value of $.01 per share. No preferred stock was issued as of December 31, 2013 and 2012.

  1. Income Taxes

Pretax income for 2013, 2012 and 2011 was taxed in the following jurisdictions:

201320122011
(In thousands)
Domestic$233,530$65,738$192,857
Foreign119,59920,46681,024
Total$353,129$86,204$273,881

The provision (benefit) for income taxes for 2013, 2012 and 2011, was as follows:

201320122011
(In thousands)
Current
U.S.$59,707$59,811$48,823
State and local8,1235,7643,434
Foreign33,24020,22831,343
Total current101,07085,80383,600
Deferred
U.S.1,500(31,246)4,792
State and local(55)(2,377)(1,103)
Foreign(4,601)(3,606)(7,265)
Total deferred(3,156)(37,229)(3,576)
Total provision for income taxes$97,914$48,574$80,024

Deferred tax assets (liabilities) at December 31, 2013 and 2012 were:

20132012
(In thousands)
Employee and retiree benefit plans$27,361$38,401
Depreciation and amortization(175,894)(170,630)
Inventories9,62710,851
Allowances and accruals9,6327,629
Interest rate exchange agreement18,16520,856
Other4,6367,059
Total$(106,473)$(85,834)

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The deferred tax assets and liabilities recognized in the Company’s Consolidated Balance Sheets as of December 31, 2013 and 2012 were:

20132012
(In thousands)
Deferred tax asset — other current assets$34,151$32,293
Deferred tax asset — other noncurrent assets4,2843,222
Total deferred tax assets38,43535,515
Deferred tax liability — accrued expenses——
Noncurrent deferred tax liability — deferred income taxes(144,908)(121,349)
Total deferred tax liabilities(144,908)(121,349)
Net deferred tax liabilities$(106,473)$(85,834)

The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to pretax income. The computed amount and the differences for 2013, 2012 and 2011 are shown in the following table:

201320122011
(In thousands)
Pretax income$353,129$86,204$273,881
Provision for income taxes:
Computed amount at statutory rate of 35%$123,595$30,171$95,858
State and local income tax (net of federal tax benefit)4,3822,4061,515
Taxes on non-U.S. earnings-net of foreign tax credits(9,683)1,189(4,522)
Effect of flow-through entities(7,267)(7,846)(6,922)
Asset impairments—28,524—
U.S. business tax credits(1,516)—(917)
Domestic activities production deduction(6,217)(5,267)(4,589)
Other(5,380)(603)(399)
Total provision for income taxes$97,914$48,574$80,024

The Company has $597 million and $468 million of undistributed earnings of non-U.S. subsidiaries as of December 31, 2013 and 2012 , respectively. No deferred U.S. income taxes have been provided on these earnings as they are considered to be reinvested for an indefinite period of time or will be repatriated when it is tax effective to do so. If these amounts were distributed to the U.S., in the form of dividends or otherwise, we would be subject to additional U.S. income taxes, which could be material. Determination of the amount of unrecognized deferred income tax liabilities on these earnings is not practicable because of the complexities with the hypothetical calculation, and the amount of liability, if any, is dependent on circumstances if and when remittance occurs. During the year ended December 31, 2013, the Company repatriated $11.7 million of foreign earnings resulting in $0.9 million of incremental income tax expense.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

A reconciliation of the beginning and ending amount of unrecognized tax benefits for 2013, 2012 and 2011 are shown in the following table:

201320122011
(In thousands)
Beginning balance January 1st$6,506$5,548$6,440
Gross increases for tax positions of prior years1,3573,0171,828
Gross decreases for tax positions of prior years(99)(98)(1,595)
Settlements(1,219)—(338)
Lapse of statute of limitations(1,421)(1,961)(787)
Ending balance December 31st$5,124$6,506$5,548

We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2013, 2012 and 2011, we had approximately $0.5 million, $0.7 million and $0.5 million, respectively, of accrued interest related to uncertain tax positions. As of December 31, 2013, 2012 and 2011, we had approximately $0.2 million, $0.5 million and $0.2 million, respectively, of accrued penalties related to uncertain tax positions.

The total amount of unrecognized tax benefits that would affect our effective tax rate if recognized is $4.5 million, $5.8 million and $5.0 million as of December 31, 2013, 2012 and 2011, respectively. The tax years 2007-2012 remain open to examination by major taxing jurisdictions. Due to the potential for resolution of federal, state and foreign examinations, and the expiration of various statutes of limitation, it is reasonably possible that the Company’s gross unrecognized tax benefits balance may change within the next 12 months by a range of zero to $1.2 million.

The Company had net operating loss and credit carry forwards for U.S. federal purposes at December 31, 2013 and 2012 of $9.4 and $13.9 million, respectively. For non-U.S. purposes, the Company had net operating loss carry forwards at December 31, 2013 and 2012 of $7.0 and $7.8 million, respectively. The federal net operating loss carry forwards are available for use against the Company’s consolidated federal taxable income and expire between 2018 and 2031. The entire balance of the non-U.S. net operating losses is available to be carried forward, with $2.7 million of these losses beginning to expire during the years 2018 through 2021. The remaining $4.3 million of such losses can be carried forward indefinitely.

At December 31, 2013 and 2012, the Company had a foreign capital loss carry forward of approximately $1.0 million and $1.0 million, respectively. The foreign capital loss can be carried forward indefinitely. At both December 31, 2013 and 2012, the Company has a valuation allowance against the deferred tax asset attributable to the foreign capital loss of $0.2 million. At December 31, 2013 and 2012, the Company had state net operating loss and credit carry forwards of approximately $22.4 million and $38.8 million, respectively. If unutilized, the state net operating loss will expire between 2020 and 2033. At December 31, 2013 and 2012, the Company recorded a valuation allowance against the deferred tax asset attributable to the state net operating loss of $0.7 million and $1.5 million, respectively.

  1. Business Segments and Geographic Information

IDEX has three reportable business segments: Fluid & Metering Technologies, Health & Science Technologies and Fire & Safety/Diversified Products. Reporting units in the Fluid & Metering Technologies segment consist of: Banjo; Energy; CFP; DDPT and WST. Reporting units in the Health & Science Technologies segment consist of: Scientific Fluidics; IOP; Sealing Solutions; Gast; Micropump and MPT. Reporting units in the Fire & Safety/Diversified Products segment consist of: Fire Suppression; Rescue; Band-It; and Dispensing Equipment.

The Fluid & Metering Technologies segment designs, produces and distributes positive displacement pumps, flow meters, injectors, and other fluid-handling pump modules and systems and provides flow monitoring and other services for the food, chemical, general industrial, water and wastewater, agricultural and energy industries. The Health & Science Technologies segment designs, produces and distributes a wide range of precision fluidics, rotary lobe pumps, centrifugal and positive displacement pumps, roll compaction and drying systems used in beverage, food processing, pharmaceutical and cosmetics, pneumatic components and sealing solutions, including very high precision, low-flow rate pumping solutions required in analytical instrumentation, clinical diagnostics and drug discovery, high performance molded and extruded, biocompatible medical devices and implantables, air compressors used in medical, dental and industrial applications, optical components and coatings for applications in the fields of scientific research, defense, biotechnology, aerospace, telecommunications and electronics manufacturing, laboratory and commercial equipment used in the production of micro and

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

nano scale materials, precision photonic solutions used in life sciences, research and defense markets, and precision gear and peristaltic pump technologies that meet exacting original equipment manufacturer specifications. The Fire & Safety/Diversified Products segment produces firefighting pumps and controls, rescue tools, lifting bags and other components and systems for the fire and rescue industry, engineered stainless steel banding and clamping devices used in a variety of industrial and commercial applications, and precision equipment for dispensing, metering and mixing colorants and paints used in a variety of retail and commercial businesses around the world.

Information on the Company’s business segments is presented below, based on the nature of products and services offered. The Company evaluates performance based on several factors, of which operating income is the primary financial measure. Intersegment sales are accounted for at fair value as if the sales were to third parties.

201320122011
(In thousands)
NET SALES
Fluid & Metering Technologies
External customers$870,720$829,320$830,821
Intersegment sales1,0943,968466
Total segment sales871,814833,288831,287
Health & Science Technologies
External customers708,940689,574606,247
Intersegment sales5,7105,6611,653
Total segment sales714,650695,235607,900
Fire & Safety/Diversified Products
External customers444,470435,364401,383
Intersegment sales5791,6891,042
Total segment sales445,049437,053402,425
Intersegment eliminations(7,383)(11,318)(3,161)
Total net sales$2,024,130$1,954,258$1,838,451
OPERATING INCOME (LOSS)(1)
Fluid & Metering Technologies(2)$211,256$146,650$164,818
Health & Science Technologies(2)136,707(62,835)106,037
Fire & Safety/Diversified Products102,73096,12085,901
Corporate office(55,180)(51,717)(52,100)
Total operating income395,513128,218304,656
Interest expense42,20642,25029,332
Other income (expense) - net(178)236(1,443)
Income before taxes$353,129$86,204$273,881

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

201320122011
(In thousands)
ASSETS
Fluid & Metering Technologies$1,025,352$1,023,143$1,072,023
Health & Science Technologies1,113,5461,102,8681,178,653
Fire & Safety/Diversified Products484,139488,886442,400
Corporate office264,540170,493143,031
Total assets$2,887,577$2,785,390$2,836,107
DEPRECIATION AND AMORTIZATION(3)
Fluid & Metering Technologies$27,633$29,637$32,368
Health & Science Technologies43,49639,98130,055
Fire & Safety/Diversified Products6,8527,1078,516
Corporate office and other1,3531,5871,447
Total depreciation and amortization$79,334$78,312$72,386
CAPITAL EXPENDITURES
Fluid & Metering Technologies$11,581$13,535$12,543
Health & Science Technologies12,28013,14012,938
Fire & Safety/Diversified Products5,0406,6545,644
Corporate office and other2,6352,1913,423
Total capital expenditures$31,536$35,520$34,548
(1)Segment operating income excludes net unallocated corporate operating expenses.
(2)Segment operating income includes asset impairment charges in 2012 of $27.7 million within the Fluid & Metering Technologies segment and $170.8 million within the Health & Science Technologies segment.
(3)Excludes amortization of debt issuance expenses.

Information about the Company’s operations in different geographical regions for the years ended December 31, 2013, 2012 and 2011 is shown below. Net sales were attributed to geographic areas based on location of the customer, and no country outside the U.S. was greater than 10% of total revenues.

201320122011
(In thousands)
NET SALES
U.S.$983,791$963,137$857,990
Europe521,491479,744492,125
Asia306,466305,185278,900
Other countries212,382206,192209,436
Total net sales$2,024,130$1,954,258$1,838,451
LONG-LIVED ASSETS — PROPERTY, PLANT AND EQUIPMENT
U.S.$124,880$127,425$124,102
Europe63,01864,13763,433
Asia24,59026,32024,570
Other countries1,0001,2791,612
Total long-lived assets — net$213,488$219,161$213,717

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

  1. Acquisitions

All of the Company’s acquisitions have been accounted for under ASC 805, Business Combinations. Accordingly, the accounts of the acquired companies, after adjustments to reflect fair values assigned to assets and liabilities, have been included in the consolidated financial statements from their respective dates of acquisition.

2013 Acquisitions

On March 18, 2013, the Company acquired the stock of FTL Seals Technology, Ltd (“FTL”). FTL specializes in the design and application of high integrity rotary seals, specialty bearings, and other custom products for the oil & gas, mining, power generation, and marine markets. Located in Leeds, England, FTL has annual revenues of approximately $22.5 million (£15.0 million). FTL, along with Precision Polymer Engineering (“PPE”), operates within the Health & Science Technologies segment as part of the Sealing Solutions group (formerly the Containment group) and will expand the range of PPE’s technology expertise and markets served. FTL was acquired for an aggregate purchase price of $34.5 million (£23.1 million) in cash. The entire purchase price was funded with borrowings under the Revolving Facility. Goodwill and intangible assets recognized as part of this transaction were $18.0 million and $13.0 million, respectively. The $18.0 million of goodwill is not deductible for tax purposes.

The purchase price for FTL has been allocated to the assets acquired and liabilities assumed based on estimated fair values at the date of the acquisition. These nonrecurring fair value measurements are classified as Level 3 in the fair value hierarchy. The Company is continuing to evaluate the initial purchase price allocations, as of the acquisition date, which will be adjusted as additional information relative to the fair values of the assets and liabilities of the business become known. Accordingly, management has used its best estimate in the initial purchase price allocation as of the date of these financial statements.

The allocation of the acquisition costs to the assets acquired and liabilities assumed, based on their estimated fair values, is as follows:

(In thousands)
Accounts receivable$3,454
Inventory4,524
Other current assets, net of cash acquired131
Property, plant and equipment1,357
Goodwill17,994
Intangible assets13,016
Total assets acquired40,476
Total liabilities assumed(5,939)
Net assets acquired$34,537

Acquired intangible assets consist of trade names, non-compete agreements, customer relationships and unpatented technology. The goodwill recorded for the acquisitions reflects the strategic fit and revenue and earnings growth potential of these businesses.

The acquired intangible assets and weighted average amortization periods are as follows:

(In thousands, except weighted average life)TotalWeighted Average Life
Trade names$1,00515
Non-compete agreements2243
Customer relationships10,9509
Unpatented technology8378
2013 acquired intangible assets$13,016

The Company incurred $1.4 million of acquisition-related transaction costs in 2013. These costs were recorded in selling, general and administrative expense and were related to completed transactions, pending transactions and potential transactions,

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

including transactions that ultimately were not completed. The Company incurred $1.8 million of non-cash acquisition fair value inventory charges in 2013. These charges were recorded in cost of sales.

2012 Acquisitions

On April 11, 2012, the Company acquired the stock of PPC. PPC specializes in optical components and coatings for applications in the fields of scientific research, aerospace, telecommunications and electronics manufacturing. Located in Boulder, Colorado, PPC operates within the Health & Science Technologies segment as a part of the IOP platform. The Company acquired PPC for an aggregate purchase price of $20.6 million in cash, which was funded from operations. Goodwill and intangible assets recognized as part of this transaction were $13.9 million and $5.1 million, respectively. The $13.9 million of goodwill is not deductible for tax purposes.

On April 30, 2012, the Company acquired the stock of ERC. ERC is a leader in the manufacture of gas liquid separations and detection solutions for the life science, analytical instrumentation and clinical chemistry markets. ERC’s pioneering products include in-line membrane vacuum degassing solutions, refractive index detectors and ozone generation systems. ERC’s original equipment degassing solutions are considered the “standard” for many of the world’s leading instrument producers. Located in Kawaguchi, Japan, ERC operates within the Health & Science Technologies segment as part of the Scientific Fluidics platform. The Company acquired ERC for an aggregate purchase price of $18.0 million (¥1.47 billion), consisting of $13.3 million in cash and assumption of approximately $4.7 million of debt. The cash payment was financed with borrowings under the Revolving Facility. Goodwill and intangible assets recognized as part of this transaction were $8.5 million and $5.6 million, respectively. The $8.5 million of goodwill is not deductible for tax purposes.

On July 20, 2012, the Company acquired the stock of Matcon. Matcon is a global leader in material processing solutions for high value powders used in the manufacture of pharmaceuticals, food, plastics, and fine chemicals. Matcon’s innovative products include the original cone valve powder discharge system and filling, mixing and packaging systems, all of which support their customers’ automation and process requirements. Matcon’s products are critical to their customers’ need to maintain clean, reliable and repeatable formulations of prepackaged foods and pharmaceuticals while helping them achieve lean and agile manufacturing. Located in Evesham, Worcestershire, England, Matcon operates within the Health & Science Technologies segment in the MPT platform. The Company acquired Matcon for an aggregate purchase price of $45.8 million (£29.1 million), consisting of $35.0 million in cash, $2.4 million of working capital adjustments paid in the second quarter of 2013, and contingent consideration valued at $8.4 million as of the opening balance sheet date. The contingent consideration amount is based on 2012 and 2013 earnings before interest, income taxes, depreciation and amortization for Matcon. In 2013, the Company paid $4.9 million for full settlement of the contingent consideration arrangement. Approximately $15.0 million of the purchase price cash payment was financed with borrowings under the Revolving Facility. Goodwill and intangible assets recognized as part of this transaction were $28.0 million and $14.1 million, respectively. The $28.0 million of goodwill is not deductible for tax purposes.

The purchase price for PPC, ERC and Matcon were allocated to the assets acquired and liabilities assumed based on estimated fair values at the date of the acquisition.

The allocation of the acquisition costs to the assets acquired and liabilities assumed, based on their estimated fair values, is as follows:

(In thousands)ERCPPCMatconTotal
Accounts receivable$5,766$877$7,768$14,411
Inventory4,2249326045,760
Other current assets, net of cash acquired9812521,8803,113
Property, plant and equipment2,7381,9365,69510,369
Goodwill8,49913,94127,94750,387
Intangible assets5,6425,10414,08124,827
Other assets1,50913531,575
Total assets acquired29,35923,05558,028110,442
Total liabilities assumed(16,074)(2,465)(12,215)(30,754)
Net assets acquired$13,285$20,590$45,813$79,688

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Acquired intangible assets consist of trade names, non-compete agreements, customer relationships and unpatented technology. The goodwill recorded for the acquisitions reflects the strategic fit and revenue and earnings growth potential of these businesses.

The acquired intangible assets and weighted average amortization periods are as follows:

(In thousands, except weighted average life)TotalWeighted Average Life
Trade names$8,97315
Non-compete agreements4703
Customer relationships11,3436
Unpatented technology4,0418
2012 acquired intangible assets$24,827

The Company incurred $2.7 million of acquisition-related transaction costs in 2012. These costs were recorded in selling, general and administrative expense and were related to completed transactions, pending transactions and potential transactions, including certain transactions that ultimately were not completed. During 2012, the Company recorded $0.9 million of fair value inventory charges associated with these acquisitions, which were recorded in cost of sales.

2011 Acquisitions

On January 31, 2011, the Company acquired the membership interests of AT Films. AT Films specializes in optical components and coatings for applications in the fields of scientific research, defense, aerospace, telecommunications and electronics manufacturing. AT Films’ core competence is the design and manufacture of filters, splitters, reflectors and mirrors with the precise physical properties required to support their customers’ most challenging and cutting-edge optical applications. Headquartered in Boulder, Colorado, AT Films operates within the Health & Science Technologies segment as a part of the IOP platform. The Company acquired AT Films for an aggregate purchase price of $34.5 million, consisting of $31.8 million in cash and contingent consideration valued at approximately $2.7 million as of the opening balance sheet date. Goodwill and intangible assets recognized as part of this transaction were $18.2 million and $11.4 million, respectively. The $18.2 million of goodwill is deductible for tax purposes.

On March 11, 2011, the Company completed the acquisition of Microfluidics. Microfluidics is a global leader in the design and manufacture of laboratory and commercial equipment used in the production of micro and nano scale materials for the pharmaceutical and chemical markets. Microfluidics is the exclusive producer of the Microfluidizer family of high shear fluid processors for uniform particle size reduction, robust cell disruption and nanoparticle creation. Microfluidics operates within the Health & Science Technologies segment as a part of the MPT platform. The Company acquired Microfluidics for an aggregate purchase price of $18.5 million in cash. Goodwill and intangible assets recognized as part of this transaction were $5.9 million and $9.7 million, respectively. The $5.9 million of goodwill is not deductible for tax purposes.

On June 10, 2011, the Company completed the acquisition of CVI Melles Griot (“CVI MG”). CVI MG is a global leader in the design and manufacture of precision photonic solutions used in the life sciences, research, semiconductor, security and defense markets. CVI MG’s innovative products are focused on the generation, control and productive use of light for a variety of key science and industrial applications. Products include specialty lasers and light sources, electro-optical components, specialty shutters and components. In addition, CVI MG produces critical components for life science research, electronics manufacturing, military and other industrial applications including lenses, mirrors, filters and polarizers. These components are utilized in a number of important applications such as spectroscopy, cytometry (cell counting), guidance systems for target designation, remote sensing, menology and optical lithography. CVI MG operates within the Health and Science Technologies segment as part of the IOP platform. The Company acquired CVI MG for an aggregate purchase price of $394.7 million, consisting of $393.3 million in cash and the assumption of approximately $1.4 million of debt. Approximately $365.0 million of the cash payment was financed with borrowings under the Revolving Facility. CVI MG is headquartered in Albuquerque, New Mexico, with manufacturing sites located on three continents. Goodwill and intangible assets recognized as part of this transaction were $208.5 million and $115.8 million, respectively. Approximately $117.7 million of goodwill is deductible for tax purposes.

The purchase price for CVI MG, AT Films and Microfluidics was allocated to the assets acquired and liabilities assumed based on estimated fair values at the date of the acquisition.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The allocation of the acquisition costs to the assets acquired and liabilities assumed, based on their estimated fair values, is as follows:

(In thousands)AT FilmsMicrofluidicsCVI MGTotal
Accounts receivable$947$1,760$23,978$26,685
Inventory8522,22652,86855,946
Other current assets, net of cash acquired738167,5628,451
Property, plant and equipment5,01956731,04936,635
Goodwill18,2205,853208,540232,613
Intangible assets11,4359,717115,777136,929
Other assets2,7315482,1125,391
Total assets acquired39,27721,487441,886502,650
Total liabilities assumed(4,766)(2,951)(48,572)(56,289)
Net assets acquired$34,511$18,536$393,314$446,361

Of the $136.9 million of acquired intangible assets, $47.0 million was assigned to the CVI Melles Griot trade name and was originally not subject to amortization, however, effective October 31, 2012, the Company began to amortize this asset over 15 years. The remaining $89.9 million of acquired intangible assets consist of patents, trade names, customer relationships, non-compete and unpatented technology. The goodwill recorded for the acquisitions reflects the strategic fit and revenue and earnings growth potential of these businesses.

The acquired intangible assets and weighted average amortization periods are as follows:

(In thousands, except weighted average life)TotalWeighted Average Life
Patents$3,01710
Trade names4,16815
Customer relationships53,8957
Non-compete agreements7932
Unpatented technology28,0486
2011 acquired intangible assets$89,921

The Company incurred $5.8 million of acquisition-related transaction costs in 2011. These costs were recorded in selling, general and administrative expense and were related to completed transactions, pending transactions and potential transactions, including certain transactions that ultimately were not completed.

  1. Share-Based Compensation

The Company maintains two share-based compensation plans for executives, non-employee directors, and certain key employees that authorize the granting of stock options, unvested shares, unvested share units, and other types of awards consistent with the purpose of the plans. The number of shares authorized for issuance under the Company’s plans as of December 31, 2013 totals 10.6 million, of which 2.7 million shares were available for future issuance. Stock options granted under these plans are generally non-qualified, and are granted with an exercise price equal to the market price of the Company’s stock at the date of grant. The majority of the options issued to employees become exercisable in four equal installments, beginning one year from the date of grant, and generally expire 10 years from the date of grant. Stock options granted to non-employee directors cliff vest after one year. Unvested share and unvested share unit awards generally cliff vest after three years for employees and non-employee directors. The Company issued 0.2 million, 0.2 million and 0.3 million of unvested shares as compensation to key employees in 2013, 2012 and 2011, respectively.

All unvested shares carry dividend and voting rights, and the sale of the shares is restricted prior to the date of vesting.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Beginning in 2013, the Company granted performance share units to selected key employees that may be earned based on IDEX total shareholder return over the three-year period following the date of grant. Performance share units (referred to as “TSR awards”) are expected to be made annually and are paid out at the end of a three-year period based on the Company’s performance. Performance is measured by determining the percentile rank of the total shareholder return of IDEX common stock in relation to the total shareholder return of the S&P Midcap 400 Industrial Group for the three-year period following the date of grant. The payment of awards following the three-year award period will be based on performance achieved in accordance with the scale set forth in the plan agreement and may range from 0 percent to 200 percent of the initial grant. A target payout of 100 percent is earned if total shareholder return is equal to the 50th percentile of the S&P Midcap 400 Industrial Group. Performance share units earn dividend equivalents for the award period, which will be paid to participants with the award payout at the end of the period based on the actual number of performance share units that are earned. Payments made at the end of the award period will be in the form of stock for performance share units and will be in cash for dividend equivalents. During the year ended December 31, 2013, the Company granted approximately 0.1 million performance share units.

The Company expenses the fair value of awards made under its share-based plans. That cost is recognized in the consolidated financial statements over the requisite service period of the grants.

Weighted average option fair values and assumptions for the period specified are disclosed in the following table:

Years Ended December 31,
201320122011
Weighted average fair value of grants$12.97$11.40$12.30
Dividend yield1.57%1.59%1.46%
Volatility30.92%32.00%32.72%
Risk-free interest rate0.17% - 4.12%0.17% - 3.96%0.28% - 5.61%
Expected life (in years)5.865.986.14

The assumptions are as follows:

•The Company estimated volatility using its historical share price performance over the contractual term of the option.
•The Company uses historical data to estimate the expected life of the option. The expected life assumption for the years ended December 31, 2013, 2012 and 2011 is an output of the Binomial lattice option-pricing model, which incorporates vesting provisions, rate of voluntary exercise and rate of post-vesting termination over the contractual life of the option to define expected employee behavior.
•The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the option. For the years ended December 31, 2013, 2012 and 2011, we present the range of risk-free one-year forward rates, derived from the U.S. treasury yield curve, utilized in the Binomial lattice option-pricing model.
•The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the contractual life of the option.

The Company’s policy is to recognize compensation cost on a straight-line basis, assuming forfeitures, over the requisite service period for the entire award. Additionally, the Company’s general policy is to issue new shares of common stock to satisfy stock option exercises or grants of unvested shares.

Weighted average performance share unit fair values and assumptions for the period specified are disclosed in the following table:

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Year Ended December 31,
2013
Weighted average fair value of grants$59.58
Dividend yield—%
Volatility28.99%
Risk-free interest rate0.40%
Expected life (in years)2.87

The assumptions are as follows:

•The Company estimated volatility using its historical share price performance over the remaining performance period as of the grant date.
•Since Monte Carlo valuation is an open form model that uses an expected life commensurate with the performance period, the expected life of the performance share units was assumed to be the period from the grant date to the end of the performance period.
•The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant with a term commensurate with the remaining performance period.
•Total Shareholder Return is determined assuming that dividends are reinvested in the issuing entity over the performance period, which is mathematically equivalent to utilizing a 0% dividend yield.

Total compensation cost for stock options is as follows:

Years Ended December 31,
201320122011
(In thousands)
Cost of goods sold$479$650$805
Selling, general and administrative expenses5,7895,6426,153
Total expense before income taxes6,2686,2926,958
Income tax benefit(2,016)(1,988)(2,208)
Total expense after income taxes$4,252$4,304$4,750

Total compensation cost for unvested shares is as follows:

Years Ended December 31,
201320122011(1)
(In thousands)
Cost of goods sold$1,380$991$684
Selling, general and administrative expenses8,4715,8194,434
Total expense before income taxes9,8516,8105,118
Income tax benefit(2,296)(1,682)(1,827)
Total expense after income taxes$7,555$5,128$3,291
(1)Reflects the forfeiture of unvested shares related to the Company’s transition to a new CEO in August 2011.

Total compensation cost for performance share units is as follows:

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Year Ended December 31,
2013
(In thousands)
Cost of goods sold$—
Selling, general and administrative expenses873
Total expense before income taxes873
Income tax benefit(280)
Total expense after income taxes$593

Recognition of compensation cost was consistent with recognition of cash compensation for the same employees.

As of December 31, 2013, there was $9.1 million, $12.3 million and $1.8 million of total unrecognized compensation cost related to stock options, time based shares and performance shares, respectively, that is expected to be recognized over a weighted-average period of 1.3 years, 1.0 year and 1.1 years, respectively.

A summary of the Company’s stock option activity as of December 31, 2013, and changes during the year ended December 31, 2013 is presented in the following table:

Stock OptionsSharesWeighted Average PriceWeighted-Average Remaining Contractual TermAggregate Intrinsic Value
Outstanding at January 1, 20133,223,742$33.166.37$43,106,153
Granted651,02250.70
Exercised(1,245,817)28.41
Forfeited/Expired(112,329)43.23
Outstanding at December 31, 20132,516,618$39.606.87$86,200,655
Vested and expected to vest at December 31, 20132,400,548$39.236.78$83,095,331
Exercisable at December 31, 20131,086,636$32.475.05$44,963,329

The intrinsic value for stock options outstanding and exercisable is defined as the difference between the market value of the Company’s common stock as of the end of the period, and the grant price. The total intrinsic value of options exercised in 2013, 2012 and 2011, was $34.3 million, $23.5 million and $21.9 million, respectively. In 2013, 2012 and 2011, cash received from options exercised was $35.3 million, $45.8 million and $33.1 million, respectively, while the actual tax benefit realized for the tax deductions from stock options exercised totaled $12.5 million, $8.6 million and $8.0 million, respectively.

A summary of the Company’s unvested share activity as of December 31, 2013, and changes during the year ending December 31, 2013 is presented in the following table:

Unvested SharesSharesWeighted-Average Grant Date Fair Value
Nonvested at January 1, 2013589,986$40.27
Granted232,41856.20
Vested(154,795)38.50
Forfeited(48,930)53.58
Nonvested at December 31, 2013618,679$40.27

Unvested share grants accrue dividends and their fair value is equal to the market price of the Company’s stock at the date of the grant.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

A summary of the Company's performance share unit activity as of December 31, 2013, and changes during the year ending December 31, 2013 is presented in the following table:

Performance Share UnitsSharesWeighted-Average Grant Date Fair Value
Nonvested at January 1, 2013—$—
Granted54,06559.58
Vested——
Forfeited(860)59.58
Nonvested at December 31, 201353,205$59.58

The Company also maintains a cash-settled share based compensation plan for certain employees. Total expense related to this plan was $3.6 million, $2.3 million and $0.8 million in 2013, 2012 and 2011 respectively. At December 31, 2013 and 2012, the Company has $2.0 million and $2.0 million, respectively, included in Accrued expenses in the Consolidated Balance Sheets and $1.0 million included in Other non-current liabilities at December 31, 2013.

  1. Other Comprehensive Income (Loss)

The components of other comprehensive income (loss) are as follows:

For the Year Ended December 31, 2013For the Year Ended December 31, 2012
Pre-taxTaxNet of taxPre-taxTaxNet of tax
(In thousands)
Cumulative translation adjustment$13,572$—$13,572$14,445$—$14,445
Pension and other postretirement adjustments
Net gain (loss) arising during the year26,274(9,859)16,415(16,607)3,107(13,500)
Amortization/settlement recognition of net loss (gain)8,599(3,226)5,3737,801(1,460)6,341
Pension and other postretirement adjustments, net34,873(13,085)21,788(8,806)1,647(7,159)
Reclassification adjustments for derivatives7,430(2,692)4,7387,571(2,791)4,780
Total other comprehensive income (loss)$55,875$(15,777)$40,098$13,210$(1,144)$12,066
For the Year Ended December 31, 2011
Pre-taxTaxNet of tax
(In thousands)
Cumulative translation adjustment$(14,108)$—$(14,108)
Pension and other postretirement adjustments
Net gain (loss) arising during the year(18,066)6,038(12,028)
Amortization or settlement recognition of net loss (gain)5,446(1,816)3,630
Pension and other postretirement adjustments, net(12,620)4,222(8,398)
Reclassification adjustments for derivatives(32,754)12,500(20,254)
Total other comprehensive income (loss)$(59,482)$16,722$(42,760)

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Amounts reclassified from accumulated other comprehensive income (loss) to net income (loss) are summarized as follows:

For the Years Ended December 31,
201320122011Income Statement Caption
Pension and other postretirement plans:
Amortization of service cost$8,599$7,801$5,446Selling, general and administrative expense
Total before tax8,5997,8015,446
Provision for income taxes(3,226)(1,460)(1,816)
Total net of tax$5,373$6,341$3,630
Derivatives:
Reclassification adjustments$7,430$7,571$(32,754)Interest expense
Total before tax7,4307,571(32,754)
Provision for income taxes(2,692)(2,791)12,500
Total net of tax$4,738$4,780$(20,254)
  1. Retirement Benefits

The Company sponsors several qualified and nonqualified pension plans and other postretirement plans for its employees. The Company uses a measurement date of December 31 for its defined benefit pension plans and post retirement medical plans. The Company employs the measurement date provisions of ASC 715, “Compensation-Retirement Benefits”, which require the measurement date of plan assets and liabilities to coincide with the sponsor’s year end.

The following table provides a reconciliation of the changes in the benefit obligations and fair value of plan assets over the two-year period ended December 31, 2013, and a statement of the funded status at December 31 for both years.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Pension BenefitsOther Benefits
2013201220132012
U.S.Non-U.S.U.S.Non-U.S.
(In thousands)
CHANGE IN BENEFIT OBLIGATION
Obligation at January 1$111,188$56,555$101,511$47,763$25,587$21,073
Service cost1,5261,3881,7561,300968763
Interest cost3,7662,1464,2472,206906922
Plan amendments——59410—159
Benefits paid(2,479)(1,957)(4,097)(3,536)(801)(704)
Actuarial loss (gain)(11,885)58113,2026,700(5,139)3,313
Currency translation—1,758—1,712(167)61
Curtailments/settlements(9,277)—(5,490)———
Acquisition——————
Obligation at December 31$92,839$60,471$111,188$56,555$21,354$25,587
CHANGE IN PLAN ASSETS
Fair value of plan assets at January 1$74,578$19,660$59,619$16,914$—$—
Actual return on plan assets14,3032,3416,1771,944——
Employer contributions(1)4,8321,84017,2873,514801704
Benefits paid(2,479)(1,957)(4,097)(3,536)(801)(704)
Currency translation—447—810——
Settlements(9,277)3(4,408)———
Other———14——
Fair value of plan assets at December 31$81,957$22,334$74,578$19,660$—$—
Funded status at December 31$(10,882)$(38,138)$(36,610)$(36,894)$(21,354)$(25,587)
COMPONENTS ON THE CONSOLIDATED BALANCE SHEETS
Current liabilities$(656)$(995)$(588)$(743)$(946)$(907)
Other noncurrent liabilities(10,226)(37,143)(36,022)(36,151)(20,408)(24,680)
Net liability at December 31$(10,882)$(38,138)$(36,610)$(36,894)$(21,354)$(25,587)
(1)Includes $10.0 million discretionary contribution to U.S. plan in 2012.

The accumulated benefit obligation (ABO) for all defined benefit pension plans was $143.5 million and $160.7 million at December 31, 2013 and 2012, respectively.

The weighted average assumptions used in the measurement of the Company’s benefit obligation at December 31, 2013 and 2012 were as follows:

U.S. PlansNon-U.S. Plans
2013201220132012
Discount rate4.61%3.56%4.03%3.91%
Rate of compensation increase4.00%3.94%3.14%2.99%

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The pretax amounts recognized in Accumulated other comprehensive income (loss) as of December 31, 2013 and 2012 were as follows:

Pension BenefitsOther Benefits
2013201220132012
U.S.Non-U.S.U.S.Non-U.S
(In thousands)
Prior service cost (credit)$170$312$275$330$(1,951)$(2,325)
Net loss22,85414,26251,24015,496(225)5,279
Total$23,024$14,574$51,515$15,826$(2,176)$2,954

The amounts in Accumulated other comprehensive income (loss) as of December 31, 2013, that are expected to be recognized as components of net periodic benefit cost during 2014 are as follows:

U.S. Pension Benefit PlansNon-U.S. Pension Benefit PlansOther Benefit PlansTotal
(In thousands)
Prior service cost (credit)$84$26$(371)$(261)
Net loss2,306851(105)3,052
Total$2,390$877$(476)$2,791

The following tables provide the components of, and the weighted average assumptions used to determine, the net periodic benefit cost for the plans in 2013, 2012 and 2011:

Pension Benefits
201320122011
U.S.Non-U.S.U.S.Non-U.S.U.S.Non-U.S.
(In thousands)
Service cost$1,526$1,388$1,756$1,300$1,759$1,078
Interest cost3,7662,1464,2472,2064,5062,320
Expected return on plan assets(5,318)(1,055)(4,687)(1,035)(4,755)(1,117)
Net amortization7,6219555,3765894,855442
Net periodic benefit cost$7,595$3,434$6,692$3,060$6,365$2,723
Other Benefits
201320122011
(In thousands)
Service cost$968$763$691
Interest cost9069221,035
Net amortization2411(156)
Net periodic benefit cost$1,898$1,696$1,570
U.S. PlansNon-U.S. Plans
201320122011201320122011
Discount rate3.56%4.45%5.20%3.91%4.68%5.35%
Expected return on plan assets7.50%8.00%8.25%5.53%5.90%6.17%
Rate of compensation increase3.94%3.90%3.90%2.99%2.96%3.37%

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The following table provides the pretax change recognized in Accumulated other comprehensive income (loss) in 2013:

Pension Benefits
U.S.Non-U.S.Other Benefits
(In thousands)
Net loss in current year$20,869$708$5,140
Prior service cost———
Amortization of prior service cost (credit)10425(373)
Amortization of net loss7,518929396
Exchange rate effect on amounts in OCI—(410)(33)
Total$28,491$1,252$5,130

The discount rates for our plans are derived by matching the plan’s cash flows to a yield curve that provides the equivalent yields on zero-coupon bonds for each maturity. The discount rate selected is the rate that produces the same present value of cash flows.

In selecting the expected rate of return on plan assets, the Company considers the historical returns and expected returns on plan assets. The expected returns are evaluated using asset return class, variance and correlation assumptions based on the plan’s target asset allocation and current market conditions.

Prior service costs are amortized on a straight-line basis over the average remaining service period of active participants. Gains and losses in excess of 10% of the greater of the benefit obligation or the market value of assets are amortized over the average remaining service period of active participants.

Costs of defined contribution plans were $8.4 million, $7.9 million and $7.8 million for 2013, 2012 and 2011, respectively.

The Company, through its subsidiaries, participates in certain multiemployer pension plans covering approximately 393 participants under U.S. collective bargaining agreements. None of these plans are considered individually significant to the Company as contributions to these plans totaled $1.1 million, $1.0 million, and $1.0 million for 2013, 2012 and 2011, respectively.

For measurement purposes, a 7.27% weighted average annual rate of increase in the per capita cost of covered health care benefits was assumed for 2013. The rate was assumed to decrease gradually each year to a rate of 4.49% for 2027, and remain at that level thereafter. Assumed health care cost trend rates have a significant effect on the amounts reported for the health care plans. A 1% increase in the assumed health care cost trend rates would increase the service and interest cost components of the net periodic benefit cost by $0.2 million and the health care component of the accumulated postretirement benefit obligation by $1.4 million. A 1% decrease in the assumed health care cost trend rate would decrease the service and interest cost components of the net periodic benefit cost by $0.2 million and the health care component of the accumulated postretirement benefit obligation by $1.2 million.

Plan Assets

The Company’s pension plan weighted average asset allocations at December 31, 2013 and 2012, by asset category, were as follows:

20132012
Equity securities66%68%
Fixed income securities34%32%
Total100%100%

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The following tables summarize the basis used to measure the defined benefit plans’ assets at fair value at December 31, 2013 and 2012:

Basis of Fair Value Measurement
Outstanding BalancesLevel 1Level 2Level 3
As of December 31, 2013(In thousands)
Equity
U.S. Large Cap$31,831$31,831$—$—
U.S. Small / Mid Cap8,7838,783——
International25,59125,591——
Fixed Income
U.S. Intermediate18,71518,715——
U.S. Short Duration8,9548,954——
U.S. High Yield1,5811,581——
International5,8125,812——
Other
Insurance Contracts331—331—
Cash and Equivalents2,6932,693——
$104,291$103,960$331$—
Basis of Fair Value Measurement
Outstanding BalancesLevel 1Level 2Level 3
As of December 31, 2012(In thousands)
Equity
U.S. Large Cap$32,496$32,496$—$—
U.S. Small / Mid Cap7,7707,770——
International20,86913,0827,787—
Fixed Income
U.S. Intermediate25,06925,069——
U.S. Short Duration————
U.S. High Yield————
International5,4895,489——
Other
Insurance Contracts326326——
Cash and Equivalents2,2192,219——
$94,238$86,451$7,787$—

Equities that are valued using quoted prices are valued at the published market prices. Equities in a common collective trust or a registered investment company that are valued using significant other observable inputs are valued at the net asset value (“NAV”) provided by the fund administrator. The NAV is based on the value of the underlying assets owned by the fund minus its liabilities. Fixed income securities that are valued using significant other observable inputs are valued at prices obtained from independent financial service industry-recognized vendors.

Investment Policies and Strategies

The investment objectives of the Company’s plan assets are to earn the highest possible rate of return consistent with the tolerance for risk as determined periodically by the Company in its role as a fiduciary. The general guidelines of asset

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

allocation of fund assets are that “equities” will represent from 50% to 60% of the market value of total fund assets with a target of 50% by June 30, 2015, and “fixed income” obligations, including cash, will represent from 40% to 50% with a target of 50% by June 30, 2015. The term “equities” includes common stock, convertible bonds and convertible stock. The term “fixed income” includes preferred stock and/or contractual payments with a specific maturity date. The Company strives to maintain asset allocations within the designated ranges by conducting periodic reviews of fund allocations and plan liquidity needs, and rebalancing the portfolio accordingly. The total fund performance is monitored and results measured using a 3- to 5-year moving average against long-term absolute and relative return objectives to meet actuarially determined forecasted benefit obligations. No restrictions are placed on the selection of individual investments by the qualified investment fund managers. The performance of the investment fund managers is reviewed on a regular basis, using appointed professional independent advisors. As of December 31, 2013 and 2012, there were no shares of the Company’s stock held in plan assets.

Cash Flows

The Company expects to contribute approximately $2.8 million to its defined benefit plans and $0.9 million to its other postretirement benefit plans in 2014. The Company also expects to contribute approximately $8.4 million to its defined contribution plan and $7.3 million to its 401(k) savings plan in 2014.

Estimated Future Benefit Payments

The future estimated benefit payments for the next five years and the five years thereafter are as follows: 2014 — $9.1 million; 2015 — $8.5 million; 2016 — $9.0 million; 2017 — $9.4 million; 2018 — $9.9 million; 2019 to 2023 — $53.0 million

  1. Quarterly Results of Operations (Unaudited)

The following table summarizes the unaudited quarterly results of operations for the years ended December 31, 2013 and 2012.

2013 Quarters2012 Quarters
FirstSecondThirdFourthFirstSecondThirdFourth(1)
(In thousands, except per share amounts)
Net sales$494,448$518,445$490,617$520,620$489,417$494,144$479,859$490,838
Gross profit211,997222,849211,509227,009202,889203,113194,840202,858
Operating income (loss)94,71299,55997,369103,87384,56988,65080,588(125,589)
Net income (loss)61,30062,56163,79967,55552,17154,35150,127(119,019)
Basic EPS$0.74$0.76$0.78$0.83$0.63$0.65$0.60$(1.45)
Diluted EPS$0.74$0.76$0.78$0.82$0.62$0.65$0.60$(1.45)
Basic weighted average shares outstanding82,19781,82981,25980,78282,80483,18082,48282,296
Diluted weighted average shares outstanding83,15282,73482,21881,85483,90284,09083,37082,296
(1)Fourth quarter 2012 includes a $198.5 million asset impairment charge.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of IDEX Corporation

We have audited the accompanying consolidated balance sheets of IDEX Corporation and subsidiaries (the “Company”) as of December 31, 2013 and 2012, and the related consolidated statements of operations, comprehensive income, shareholders’ equity, and cash flows for each of the three years in the period ended December 31, 2013. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the consolidated financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such consolidated financial statements present fairly, in all material respects, the consolidated financial position of IDEX Corporation and subsidiaries as of December 31, 2013 and 2012, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2013, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the Company’s internal control over financial reporting as of December 31, 2013, based on the criteria established in Internal Control — Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 13, 2014, expressed an unqualified opinion on the Company’s internal control over financial reporting.

Deloitte & Touche LLP
Chicago, Illinois
February 13, 2014

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of IDEX Corporation

We have audited the internal control over financial reporting of IDEX Corporation and subsidiaries (the “Company”) as of December 31, 2013, based on criteria established in Internal Control — Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission. The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed by, or under the supervision of, the company’s principal executive and principal financial officers, or persons performing similar functions, and effected by the company’s board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”). A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2013, based on the criteria established in Internal Control — Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated financial statements as of and for the year ended December 31, 2013, of the Company and our report dated February 13, 2014, expressed an unqualified opinion on those consolidated financial statements.

Deloitte & Touche LLP
Chicago, Illinois
February 13, 2014

MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

Internal control over financial reporting refers to the process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America, and includes those policies and procedures that:

•Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
•Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and
•Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk. Management is responsible for establishing and maintaining effective internal control over financial reporting for the Company. Management has used the framework set forth in the report entitled “Internal Control — Integrated Framework” (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission to assess the effectiveness of the Company’s internal control over financial reporting. Management has concluded that the Company’s internal control over financial reporting was effective as of December 31, 2013.

The effectiveness of the Company’s internal control over financial reporting as of December 31, 2013, has been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their report which appears herein.

Andrew K. Silvernail
Chairman of the Board and Chief Executive Officer
Heath A. Mitts
Vice President and Chief Financial Officer
Lake Forest, Illinois
February 13, 2014

Previous: Item 7A. Quantitative and Qualitative Disclosures About Market Risk. · Next: Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.